Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Classical hematology 1

Conditions

Breast Neoplasms 19Neutropenia 13Hodgkin Disease 5Lymphoma 4Lymphoma, Large B-Cell, Diffuse 3Chemotherapy-induced Neutropenia 3Triple Negative Breast Neoplasms 2Febrile Neutropenia 2Dendritic Cell Sarcoma, Interdigitating 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Sarcoma, Synovial 1Sarcoma 1Rhabdomyosarcoma 1Recurrent Uterine Corpus Carcinoma 1Rectal Neoplasms 1Neurofibrosarcoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lung Neoplasms 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Heart Failure 1Fibrosarcoma 1Fever 1Endometrial Adenocarcinoma 1

Interventions

Fluorouracil 61Leucovorin 56Oxaliplatin 51Capecitabine 42Irinotecan 29Bevacizumab 21Radiotherapy 17Cetuximab 12Folfox protocol 11Chemoradiotherapy 11Neoadjuvant Therapy 10Chemotherapy, Adjuvant 9Surgical Procedures, Operative 6Drug Therapy 6XELOX 5Panitumumab 4Laparoscopy 4FOLFOXIRI protocol 4Transanal Endoscopic Microsurgery 3Radiation 3Octreotide 3IFL protocol 3Floxuridine 3Diathermy 3Celecoxib 3vatalanib 2spartalizumab 2Trinitrotoluene 2Tegafur 2Semaxinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Rectal Neoplasms × pegfilgrastim × Clear all
NCT00911170 2017-12-29

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Amgen

Phase 3 Completed
847 enrolled 21 charts
Classical hematologyGastrointestinal

Colonic Neoplasms, Fever, Neoplasms, Neutropenia, Rectal Neoplasms, Colorectal Neoplasms, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡